Madrid

• An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in … Ended
  2023-505851-33-00 5 2024-07-29 Dravet Syndrome
• A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended
  2023-509412-28-00 4 2024-07-26 Type 2 Diabetes
• Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/​Refractory Multiple Myeloma to Proteasome In … Ended
  2024-515650-24-00 4 2024-07-26 Multiple Myeloma
• A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants with Chronic Rhinosinusitis with Nasal Polyps on a Bac … Ended
  2023-508231-31-00 4 2024-07-24 Chronic Rhinosinusitis with Nasal Polyps
• Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia Ended
  2023-508819-23-00 3 2024-07-24 Primary immune thrombocytopenia (ITP)
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian … Ended
  2023-508149-42-00 3 2024-07-16 Infertility in women undergoing assisted reproductive technologies (AR
• A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended
  2022-502982-49-00 4 2024-07-15 Metastatic Castration-Resistant Prostate Cancer
• A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment … Ended
  2023-509738-20-00 6 2024-07-11 Plaque Psoriasis
• A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodec … Ended
  2023-505086-83-00 4 2024-07-10 Tourette Syndrome
• Randomised, crossover bioequivalence clinical trial of linagliptin/metformin 2.5 mg/1000 mg film-coated tablets, after a single oral dose ad … Ended
  2024-512310-18-00 2 2024-07-08 diabetes
• Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended
  2023-505903-22-00 4 2024-07-02 Sepsis associated acute kidney injury
• Bioequivalence clinical trial of two formulations of dapagliflozin. Ended
  2023-506561-62-00 2 2024-07-01 Healthy volunteers
• A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1 … Ended
  2023-509001-76-00 5 2024-07-01 Asthma
• Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended
  2023-506210-40-00 5 2024-06-28 Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
• A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa … Ended
  2023-508377-82-00 10 2024-06-27 Hidradenitis Suppurativa (HS)
• A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced l … Ended
  2023-509644-10-00 9 2024-06-27 Advanced Non-small Cell Lung Cancer
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop … Ended
  2023-506558-20-00 5 2024-06-26 Dermatitis atopic
• An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal … Ended
  2023-507350-33-00 5 2024-06-25 Thyroid eye disease
• An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig … Ended
  2023-508356-19-00 4 2024-06-25 Pancreatic adenocarcinoma metastatic
• A safety study of PF-08046045/SGN-35T in adults with advanced cancers Ended
  2022-502390-41-00 1 2024-06-20 Enteropathy-Associated T-Cell Lymphoma
• A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokine … Ended
  2022-502963-39-00 7 2024-06-20 Glycogen storage disease type 1a (GSD1a)
• A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT) Ended
  2023-507410-27-00 4 2024-06-19 Severe Asthma
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer

Showing 2,737–2,760 of 3,550 trials